Background: Chimeric antigen receptor (CAR) T cells are a promising therapy for hematologic
INTRODUCTION
Despite advances in multiple myeloma (MM) therapy, the disease remains incurable in most patients, and novel approaches are needed. B-cell maturation antigen (BCMA) is a cell surface receptor expressed primarily by plasma cells. Its ligands are BAFF and APRIL, and it functions to maintain long-lived plasma cell homeostasis (1). BCMA is expressed consistently on MM cell lines and primary patient samples, though intensity of expression is variable (2) (3) (4) (5) .
BCMA is shed from the surface of plasma cells by gamma-secretase-mediated cleavage(6), leading to a soluble form (sBCMA) that is detectable in circulation. Higher concentrations of sBCMA in myeloma patients are associated with poorer clinical outcomes (7) . Ligation of BCMA promotes MM cell proliferation, survival, and drug resistance (8, 9) . and antibody-based blockade of BCMA signaling has anti-MM activity in pre-clinical models (3, 9) . Thus, BCMA is a rational target for anti-myeloma therapy.
Chimeric antigen receptors (CARs) provide novel specificity to T cells, coupling antibody-based extracellular domains to T-cell signaling domains and co-stimulatory molecules.
We previously reported that CD19-specific CAR T cells given after salvage autologous stem cell transplant could prolong remission duration in some relapsed/refractory MM patients (10, 11) .
Carpenter et al. demonstrated pre-clinical anti-MM activity using BCMA-specific CAR T cells (4) , and adoptive transfer of autologous T cells expressing this murine BCMA CAR, following lymphodepletion with fludarabine and cyclophosphamide conditioning, induced objective responses in 4/12 heavily-pretreated MM patients. Responses were associated with significant but expected toxicities including cytokine release syndrome (CRS) and neurotoxicity (12) , similar to those described with CD19-targeted CAR T cells in patients with B-cell malignancies (13, 14) .
CART-BCMA FOR REFRACTORY MM 6 We have developed a novel BCMA-targeted CAR with a fully human scFv (single chain variable fragment), fused to the hinge and transmembrane domain of CD8 and the human 4-1BB and CD3ζ intracellular signaling domains and packaged in a lentiviral vector, with demonstrated pre-clinical activity (15) . We now report results from our phase 1 clinical trial evaluating autologous T cells expressing this fully human BCMA-specific CAR (CART-BCMA) in relapsed/refractory myeloma patients, both with and without lymphodepleting chemotherapy. Anti-myeloma therapy could resume during manufacturing until 2 weeks prior to first CART-BCMA infusion. CART-BCMA cells were administered in an outpatient research unit over 3 days as split-dose intravenous infusions (10% of dose given on day 0; 30% on day 1, and 60% on day 2). In cohorts 2 and 3, Cy was administered for lymphodepletion 3 days prior to first CART-BCMA infusion (Fig. 1) .
RESULTS

This
From November 2015 -December 2017, 34 subjects consented and 29 were eligible and commenced manufacturing, with 25 receiving CART-BCMA infusions. Four were not treated due to rapid disease progression and clinical deterioration during manufacturing and bridging therapy (Suppl. Fig. S1 ). Baseline characteristics and prior lines of therapy are summarized in Table 1 , with individual details shown in Suppl. Table S2 . Subjects had a median of 7 prior lines of therapy, with 96% dual refractory to a proteasome inhibitor (PI) and immunomodulatory drug (IMID), 72% refractory to daratumumab, and 44% penta-refractory to bortezomib, lenalidomide, carfilzomib, pomalidomide, and daratumumab. Ninety-six % had at least 1 high-risk cytogenetic abnormality; 68% had either deletion 17p or a TP53 mutation. Baseline tumor burden was high (median 65% myeloma cells on bone marrow biopsy), and 28% had extramedullary disease.
For all subjects, the minimum target goal of CART-BCMA cells was successfully manufactured and formulated, though 1 subject required 2 leukaphereses and manufacturing attempts. Final products comprised a median of 97% CD3+ T cells, with median CD4:CD8 ratio of 1.7. Twenty-one subjects received all 3 planned CART-BCMA infusions, with 4 receiving 40% of planned dose (3 rd infusion held due to early CRS). Further details of manufacturing, product characteristics, and dosing for each subject are shown in Suppl. Table S3 .
Grade 3 or higher adverse events, regardless of attribution, were seen in 24/25 subjects (96%) and are summarized in Table 2 , with individual adverse events for each subject listed in Suppl. Table S4 . Twenty-four of 25 subjects (96%) were admitted to the hospital a median of 4 days (range 1 -28) after first CART-BCMA infusion, with longer time to admission in Cohort 2
(1-5 x 10 7 CART-BCMA cells, median 8 days) than Cohorts 1 and 3 (1-5 x 10 8 CART-BCMA cells, median 3 days for both). Cytokine release syndrome (CRS) was observed in 22/25 subjects (88%), and was grade 3-4 on the Penn grading scale (16) (Suppl . Table S1 ) in 8 (32%), all of whom were treated at the 1-5 x 10 8 dose. Median time to CRS onset was 4 days (range 1-11), with a median duration of 6 days (range 1 -18), and median duration of hospitalization of 7 days (range 0 -40). CRS was associated with elevations in ferritin and C-reactive protein, as described previously (14) . Seven subjects (28%) received IL-6 blockade with either tocilizumab (n=6) or siltuximab (n=1).
Neurotoxicity was seen in 8/25 subjects (32%), and was mild (grade 1-2) in 5 (transient confusion and/or aphasia). Three (12%) had grade 3-4 encephalopathy including 1 subject (03) in cohort 1 with a DLT of PRES (posterior reversible encephalopathy syndrome) with severe obtundation, recurrent seizures and mild cerebral edema on MRI (magnetic resonance imaging) that fully resolved after treatment with high-dose methylprednisolone (1 g/day x 3) and cyclophosphamide 1.5 g/m 2 . The others had no objective changes on MRI. All 3 subjects with severe neurotoxicity had high tumor burden (2 with extramedullary disease), had received a dose of 5 x 10 8 CART-BCMA cells, and had grade 3 or 4 CRS. A summary of CRS and neurotoxicity based on cohort is provided in Suppl. respectively. All other subjects have progressed, and median progression-free survival (PFS) is 65, 57, and 125 days for cohorts 1, 2, and 3, respectively (Suppl. Fig S2) . At time of data cut-off, 13 subjects had expired, with median overall survival of 502 days for all subjects (Suppl. Fig S2) , and 359 days, 502 days, and not reached for cohorts 1, 2, and 3, respectively (Fig. 2C ).
All infused subjects had detectable CART-BCMA cells in peripheral blood by qPCR ( Fig. 3A-3C), and 24/25 had detectable CAR+ T cells by flow cytometry (Suppl. Fig. S4-S6 ; Suppl.
Fig . S3 for representative staining). Expansion generally peaked at day 10-14, and appeared most uniform in cohort 3 with Cy conditioning and the higher dose of CART-BCMA cells, while it was more heterogeneous in cohorts 1 and 2, though this difference did not meet statistical significance (Fig. 3D) . Despite a predominance of CD4+ T cells in the infused product, CART-BCMA cells circulating in blood were predominantly CD8+, and were highly activated, with a median of 94%
(range 21 -94%) of CAR+CD3+ cells expressing HLA-DR during peak expansion (Suppl. Table   S6 ). CART-BCMA levels in marrow aspirates generally mirrored those in peripheral blood, and also were elevated in pleural fluid and cerebrospinal fluid for subject 03, and pleural fluid from subject 27, demonstrating widespread trafficking (Suppl. Table S7 ). Following peak expansion, CART-BCMA cell levels by qPCR declined in a log-linear fashion in the majority of patients Table S9 for full analysis). Peak fold-increase in IL-6 was strongly associated with both severe CRS and neurotoxicity (Suppl . Tables S8, S9) ; however, tocilizumab and siltuximab administration can artificially elevate serum IL-6 levels (17). When only IL-6 values obtained prior to administration of tocilizumab (n=6) or siltuximab (n=1) were included in the analyses, the association of peak IL-6 fold-increase with severe CRS and neurotoxicity was still present, but less statistically robust ( Fig. 4H-I ). We did not observe significant differences in peak fold cytokine increases between Cohorts 1 and 3, which received the same dose of CART-BCMA cells with or without Cy conditioning, respectively (Suppl. Fig S7) .
We also assessed serum concentration of sBCMA, as well as its ligands BAFF and APRIL. Compared to a panel of healthy donors (HD), enrolled subjects had significantly elevated sBCMA and reduced APRIL levels at baseline, with high variability amongst subjects ( Fig. 5A ). BAFF concentrations in subjects were not significantly different from HD. Serial assessments of serum sBCMA showed decreases following CART-BCMA infusions, which were more pronounced in responding compared to non-responding subjects ( 
S11-S12).
In order to explore other pre-treatment characteristics potentially associated with expansion and/or response, we analyzed features of the CART-BCMA product before, during, and at end of manufacturing. We found that a higher CD4:CD8 T cell ratio in the leukapheresis product, pre-manufacturing, was associated with greater in vivo CART-BCMA expansion (Fig.   6E ), and to a lesser degree, response (Fig 6F) , while absolute CD3+, CD4+, or CD8+ T cell numbers in the leukapheresis product, or CD4:CD8 ratio in the final CART-BCMA product at end of manufacturing was not (data not shown). Fold expansion of seeded cells during manufacturing also correlated with in vivo CART-BCMA expansion (Fig. 6G ), suggesting that in vitro proliferative capacity may predict for in vivo activity. Finally, our previous analyses in CLL patients receiving CD19-directed CAR T cells demonstrated that deeper clinical responses were associated with a higher percentage of CD27+CD45RO-CD8+ T cells within the leukapheresis product (18), a phenotype that identifies primarily naïve but also includes stem cell memory T cell populations (19) . We examined CD8+ T cells within the leukapheresis products in subjects treated with CART-BCMA cells and similarly found that subjects with higher frequencies of CD27+CD45RO-CD8+ T cells were more likely to have robust in vivo expansion and clinical response ( Fig. 6H-I ).
DISCUSSION
CAR T cell therapy is emerging as a promising therapeutic option for B-cell malignancies, with the potential for durable disease control following a single treatment, differentiating it from other therapies that require repeated and/or continuous administration. In this report, we demonstrate the potential of CAR T cell therapy in advanced refractory myeloma, with 12/25 subjects (48%) achieving a partial response or better, including 7/11 (64%) treated in Cohort 3 with lymphodepleting chemotherapy and the higher (>10 8 ) dose of CART-BCMA cells. Three subjects had ongoing remissions >11 months after CART-BCMA therapy, including one ongoing sCR at 2.5 years. This is notable given the highly adverse biological features of the enrolled subjects' myeloma, including high tumor burden, rapidly progressing disease, and high-risk genetics, and further validates BCMA as a highly-attractive target in myeloma. Importantly, this activity was seen despite the fact that our study, unlike the previously-reported NCI study, did not exclude patients with low BCMA expression or high tumor burden, and used either no lymphodepletion or Cy alone, compared with Cy + fludarabine in the prior study (12, 20) . We successfully manufactured CAR T cell products from all apheresed subjects, and saw engraftment in all subjects as well, though peak levels and persistence of CAR T cells were variable.
Myeloma has long been associated with quantitative and functional deficits in T cells, particularly in more advanced, refractory disease, with inverted CD4:CD8 T cell ratios, impaired ex vivo anti-tumor activity, and acquisition of an exhausted or senescent phenotype (21) (22) (23) .
Responses correlated with degree of in vivo expansion in our study, which in turn was associated with higher pre-manufacturing CD4:CD8 T cell ratio, pre-manufacturing frequency of CD45RO-CD27+CD8+ T cells, and magnitude of in vitro proliferation during manufacturing. This suggests that more effective CART-BCMA products may be derived from subjects with a less differentiated, more naïve and/or stem cell memory-like T cell compartment, as previously observed in a CLL trial at our center using CD19-directed CAR T cells (18) . Confirmation with larger numbers and other CAR T cell products is necessary, but these data suggest that pretreatment phenotypic and/or functional T cell characteristics may aid in the prediction of response to CART-BCMA therapy. They also suggest that treatment of patients earlier in the course of their disease, when T cells may be intrinsically "fitter," or modifying manufacturing techniques to generate more phenotypically favorable CAR+ T cells, may be more effective. Alternatively, routine harvesting and storage of T cells early in disease course (e.g. in first remission) for later use in CAR manufacturing could be considered.
Successful adoptive transfer of tumor-specific T cells, including CAR T cells, in humans has most commonly followed some form of lymphodepleting conditioning (13, 14, (24) (25) (26) , which has been demonstrated to enhance T cell-mediated anti-tumor immunity via multiple potential mechanisms, including reduction of cellular "sinks" leading to increased availability of homeostatic cytokines, and depletion of suppressor cell populations, among others (27). Our study demonstrates that lymphodepletion is not absolutely required for robust and sustained CAR T cell expansion and clinical activity, as seen with subjects 01 and 03 in Cohort 1. However, we observed short-term expansion more consistently in Cohort 3, where subjects received Cy conditioning, compared to Cohort 1 (Fig 3) , demonstrating an effect of lymphodepletion on CAR-T cell kinetics following adoptive transfer. Given studies showing that incremental increases in the intensity of the conditioning leads to enhanced engraftment and clinical outcomes (13, 24) , it is possible that modifying the lymphodepletion (e.g. adding fludarabine to Cy) may further augment the activity of CART-BCMA cells, and we are testing this in ongoing trials.
An important unanswered question for BCMA-targeted CAR T cells is whether there is a threshold of BCMA expression on MM cells required for optimal recognition and killing. In the previously-reported NCI trial, 52/85 (62%) of pre-screened bone marrow biopsies stained for BCMA by IHC met their pre-specified threshold for eligibility, meaning more than a third of potentially eligible MM patients would have been excluded (12) . We did not require any specific level of BCMA as an eligibility requirement, and identified MM cell BCMA expression by flow cytometry in all subjects, consistent with recent data that flow cytometry is more sensitive than IHC for this purpose (28). Baseline BCMA intensity by flow cytometry did not correlate with either expansion or response in our study (Suppl. Figs. S9-S10), suggesting that excluding patients based on baseline BCMA expression is likely not necessary.
The observed dynamics of BCMA surface expression on MM cells, with the residual MM cells from several subjects in this study having significantly diminished BCMA intensity following CAR T cell therapy (Fig 5) , highlights an important area for future research into resistance to CART-BCMA therapy. Down-modulation of BCMA expression was also observed in at least 1 subject in the NCI study (20) , suggesting that it may be a common means of MM cell escape from BCMA-directed CAR-T cell therapies. Surface BCMA expression subsequently increased in most subjects upon progression, suggesting a transcriptional or post-translational mechanism, such as increased shedding from the cell surface. Alternatively, there may be immune selection for BCMA-dim/negative clonal variants, which are subsequently outcompeted by residual BCMA+ clones upon loss of CART-BCMA cell activity. This suggests that most patients progressing after CART-BCMA will remain candidates for additional BCMA-targeted therapies.
Our prior studies of CD19-specific CAR T cells in CLL and ALL suggest that durability of remission is associated with long-term persistence of CAR T cells (14, 16) . In this study, however, only 1 (subject 01) of the 3 long-term responders (subjects 01, 19, 33) had detectable CART-BCMA cells by flow cytometry after day 60 (Suppl. Figs.S4, S6). All 3 had detectable CAR T cells by qPCR at 3 months, but the amount of detectable BCMA CAR transgene (measured as copies/µg genomic DNA) in subjects 19 and 33 was similar to or less than several other patients who ultimately progressed between months 3 and 6 (Suppl . Table S6 ). Thus, in myeloma, CAR T cell persistence alone may not be enough to predict long-term durability of remission, and other factors, such as T cell functionality, antigen expression, and/or immunosuppressive elements in the tumor microenvironment may play a role.
The primary toxicities of CAR T cells remain cytokine release syndrome (CRS) and neurotoxicity. The frequency and severity of CRS in this study was similar to that reported in our CD19-targeted CAR T cell trials (14, 16) , and was abrogated with IL-6 receptor blockade therapy.
Though patient numbers are small, peak serum cytokine increases did not appear to differ significantly with or without Cy lymphodepletion, when CAR T cell dose was kept the same (Cohort 1 vs. 3, Suppl. Fig. S7 ). Interestingly, however, median peak fold-increases of IL-6 and several other cytokines (e.g. IFN-γ, IL-10, GMCSF, IL-17) in this study were 1 to 2 orders of magnitude lower than that reported in the NCI BCMA CAR T cell study (20) , despite a higher tumor burden in our study, and despite the fact that our analysis of peak IL-6 levels included values obtained after tocilizumab administration, which is known to transiently further increase IL-6 levels due to binding of IL-6 receptor (17). One explanation for this difference may be the co-stimulatory domains used within the 2 CAR constructs, since CD28 domains, such as that used in the NCI CAR construct, have been associated with more rapid CAR T cell proliferation and cytokine release than 4-1BB domains (29), as used in our CAR construct. However, the small numbers of patients and multiple differences between the studies with regards to inclusion criteria, dose, schedule, and lymphodepletion regimen preclude definitive conclusions.
Neurotoxicity has been reported in up to 50% of subjects in some CAR T cell trials (13, 30, 31), can occur concurrently with or subsequent to CRS, often does not improve with tocilizumab, and is reversible in most, but not all, cases. Neurotoxicity has been associated with early onset of CRS and rapid elevation of inflammatory cytokines both within the serum and CNS, perhaps leading to increased CNS vascular permeability (32). Consistent with this, we identified peak serum increases of IL-6, IFN-γ, and MIP-1α as most associated with neurotoxicity in this study (Fig. 4) . Interestingly, neurotoxicity was also associated with peak fold increase in
IL-1RA, an endogenous inhibitor of the pro-inflammatory effects of IL-1α and IL-1β, which have been implicated in CAR T cell-associated neurotoxicity (33, 34). This perhaps reflects induction
of an (ultimately ineffective) feedback mechanism in patients with neurotoxicity, and suggests that augmenting IL-1 blockade with the recombinant IL-1RA anakinra may have therapeutic benefit, as demonstrated in pre-clinical models (33, 34). Our experience demonstrating rapid reversal of a PRES-like syndrome in subject 03 suggests that cyclophosphamide may also be an option in steroid-refractory cases.
In summary, autologous T cells expressing a fully human BCMA-specific CAR could expand and induce objective responses, both with and without lymphodepleting chemotherapy, in subjects with advanced, refractory MM, and represent a promising new therapeutic approach.
The toxicity profile appears similar to that seen with CD19-directed CAR T cells in B-cell malignancies. Challenges include disease progression during manufacturing, potential for antigen escape due to changes in BCMA expression, and durability of responses. Subsequent studies exploring less heavily-pretreated/refractory patient populations, dual-antigen-targeting CAR constructs, novel lymphodepletion regimens or manufacturing protocols, and off-the-shelf CART products may further optimize the safety and long-term efficacy of this approach.
METHODS
Study Design and Participants
Eligible subjects had relapsed and/or refractory MM after at least 3 prior regimens, or 2 prior regimens if dual-refractory to a proteasome inhibitor (PI) and immunomodulatory drug (IMiD). Other key eligibility criteria at screening included ECOG (Eastern Cooperative
Oncology Group) performance status of 0-2; serum creatinine ≤ 2.5 mg/dL or estimated creatinine clearance ≥30 ml/min; absolute neutrophil count ≥1000/µl and platelet count ≥50,000/µl due to suboptimal efficacy, and allowed up to 13 subjects in cohort 3; however, funding limitations ultimately ended enrollment after 11 treated Cohort 3 subjects (total n=25 treated).
The study was designed by the lead authors and was conducted according to principles of Good Clinical Practice. An independent data safety monitoring board reviewed adverse event data and provided oversight. Data cut-off for analysis was July 9, 2018.
Procedures
After a 2-week washout from therapy (4 weeks for monoclonal antibodies), subjects underwent steady-state leukapheresis to collect T cells for CART-BCMA manufacturing. Antimyeloma therapy could resume during manufacturing until 2 weeks prior to first CART-BCMA infusion. CART-BCMA cells were administered intravenously over 3 days (10% of dose on day 0; 30% on day 1, and 60% on day 2), as described. (16) Table S1 ) (16) . Myeloma responses were assessed by updated
International Myeloma Working Group criteria (38).
Research sample processing, freezing, and laboratory analyses were performed in the Translational and Correlative Studies Laboratory at the University of Pennsylvania, as described (14, 16, 35) . CART-BCMA cells were quantified from peripheral blood or bone marrow samples by flow cytometry and quantitative PCR. Reagents and protocols for flow cytometry are described in the Supplementary Methods. Genomic DNA was isolated directly from whole blood or marrow aspirate, and qPCR analysis was performed using ABI TaqMan technology and a validated assay to detect the integrated CAR transgene sequence as per Supplementary Methods and described (35).
Serum cytokine levels were assessed on batched cryopreserved samples using the human cytokine magnetic 30-plex panel (LHC6003M) from Life Technologies, as described (14) .
Measurement of soluble BCMA, BAFF, and APRIL concentrations in serum was performed by ELISA using antibody sets for human BCMA (DY193), APRIL (DY884B) and BAFF (DT124-05) from R&D Systems. See Supplementary Methods for details.
Flow cytometric assessment of MM cells, including BCMA expression, on fresh bone marrow aspirate material was adapted from the EuroFlow protocol (39) as described in Supplementary Methods. Flow cytometric assessment of T cell phenotype in cryopreserved leukapheresis specimens was performed and analyzed as described (18) .
Outcomes
The primary objective was to evaluate the safety of CART-BCMA in patients with relapsed/refractory myeloma. The primary endpoint was incidence of study-related grade 3 or higher AEs, including dose-limiting toxicities (DLTs). A DLT was defined as a serious AND unexpected AE whose relationship to study therapy could not be ruled out, occurring within 4 weeks of receiving protocol therapy. Hematologic toxicity was not considered a DLT due to the refractory nature of the underlying disease and expected myelosuppression from cyclophosphamide. In addition, any death related to protocol treatment, as well as any expected grade 4 organ toxicity or grade 4 neurologic toxicity that did not resolve or improve to grade 2 or less within 4 weeks of onset, despite medical management, was also considered a DLT.
Secondary objectives were to assess feasibility of manufacturing CART-BCMA cells, and clinical activity. Secondary endpoints were frequency of successful manufacturing, and clinical outcomes, including response rates, progression-free survival, and overall survival. Exploratory endpoints included CART-BCMA expansion and persistence in vivo; changes in concentration of serum cytokines and soluble BCMA, and expression of BCMA on MM cells.
Statistical analysis
Statistical analysis of the study is primarily descriptive due to the pilot nature of the trial and small sample size of each cohort. Kaplan-Meier method was used to estimate duration of response, progression-free and overall survival and the associated median survival times.
Association between a binary endpoint (e.g. response) and a continuous factor (e.g. CAR T cell numbers) was evaluated using the Mann-Whitney test, or Kruskal-Wallis test if more than two groups were compared simultaneously. Association between a binary endpoint and a categorical factor (e.g. presence or absence of deletion 17p) was evaluated using Fisher's Exact test.
Spearman correlations were used to measure the correlations between two continuous variables.
Significance of the Spearman correlation against the null hypothesis of no correlation was 
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